, Tumeurs (CIT) funded and developed by the Ligue Nationale Contre le Cancer. It was supported by the 'Ligue contre le Cancer, Calvados and Orne Committee), the 'Conseil Regional de Basse-Normandie', and the French Government
were recipients of a doctoral fellowship from the 'Ligue contre le Cancer' (Calvados CommitteeF.) and C.D. was recipient of a post-doctoral fellowship from the 'Conseil Regional de Basse-Normandie'. N.V. was a recipient of a doctoral fellowship from the French Ministry for Higher Education and Research. The present study was supported by a grant from l, Eure Committee: M.M ,
Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells???, Gynecologic Oncology, vol.105, issue.1, pp.31-44, 2007. ,
DOI : 10.1016/j.ygyno.2006.12.011
Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family, Journal of Ovarian Research, vol.6, issue.1, pp.38-2013, 2013. ,
DOI : 10.1016/j.ccr.2012.02.028
URL : https://hal.archives-ouvertes.fr/hal-00840946
and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis, International Journal of Cancer, vol.119, pp.885-895, 2010. ,
DOI : 10.3748/wjg.v12.i46.7472
URL : https://hal.archives-ouvertes.fr/hal-01650312
Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy, Carcinogenesis, vol.61, issue.4, pp.984-993, 2010. ,
DOI : 10.1016/j.addr.2009.05.002
Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells, Molecular Cancer Therapeutics, vol.8, issue.11, pp.3162-3170, 2009. ,
DOI : 10.1158/1535-7163.MCT-09-0493
Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis, Apoptosis, vol.77, issue.4, pp.492-508, 2013. ,
DOI : 10.1124/mol.109.060780
URL : https://hal.archives-ouvertes.fr/inserm-00872602
experiment in human serous ovarian carcinoma, International Journal of Cancer, vol.17, issue.106, pp.340-350, 2015. ,
DOI : 10.1073/pnas.0905056106
-Targeting Strategies, Journal of Medicinal Chemistry, vol.58, issue.4, pp.1644-1668, 2015. ,
DOI : 10.1021/jm500672y
Diagnosing and exploiting cancer's addiction to blocks in apoptosis, Nature Reviews Cancer, vol.417, issue.2, pp.121-132, 2008. ,
DOI : 10.1038/bjc.1972.33
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members, Cancer Cell, vol.9, issue.5, pp.351-365, 2006. ,
DOI : 10.1016/j.ccr.2006.03.027
Small molecule Mcl-1 inhibitors for the treatment of cancer, Pharmacology & Therapeutics, vol.145, pp.76-84, 2015. ,
DOI : 10.1016/j.pharmthera.2014.08.003
Evaluation and critical assessment of putative MCL-1 inhibitors, Cell Death & Differentiation, vol.15, issue.11, pp.1475-1484, 2013. ,
DOI : 10.1593/neo.13230
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death & Disease, vol.15, issue.1, p.1590, 2015. ,
DOI : 10.1172/JCI39964
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing, Chemistry & Biology, vol.19, issue.8, pp.937-954, 2012. ,
DOI : 10.1016/j.chembiol.2012.07.011
Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge, Expert Opinion on Drug Delivery, vol.14, issue.9, pp.1481-1495, 2014. ,
DOI : 10.1038/nature04303
Delivery of RNAi therapeutics: work in progress, Expert Review of Medical Devices, vol.7, issue.3, pp.781-811, 2013. ,
DOI : 10.1038/sj.embor.7400637
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo, Proceedings of the National Academy of Sciences, vol.3, issue.8, pp.12177-12182, 2005. ,
DOI : 10.4161/cbt.3.8.994
A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics, Cancer Research, vol.64, issue.10, pp.3365-3370, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-2682
Atelocollagen-mediated siRNA delivery: future promise for therapeutic application, Therapeutic Delivery, vol.5, issue.2012, pp.369-371, 2014. ,
DOI : 10.2131/jts.36.751
Fiber molecular model of atelocollagen???small interfering RNA (siRNA) complex, International Journal of Biological Macromolecules, vol.37, issue.5, pp.283-286, 2005. ,
DOI : 10.1016/j.ijbiomac.2005.11.008
Biomaterials for Gene Delivery Atelocollagen-mediated Controlled Release of Molecular Medicines, Current Gene Therapy, vol.1, issue.1, pp.31-52, 2001. ,
DOI : 10.2174/1566523013348887
Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts, Int J Oncol, vol.36, pp.69-76, 2010. ,
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer, Molecular Cancer Therapeutics, vol.7, issue.9, pp.2904-2912, 2008. ,
DOI : 10.1158/1535-7163.MCT-08-0473
Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer, International Journal of Cancer, vol.58, issue.12, pp.2978-2990, 2009. ,
DOI : 10.1016/S0962-8924(01)02124-9
Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo, Nucleic Acids Research, vol.32, issue.13, pp.109-2004, 2004. ,
DOI : 10.1093/nar/gnh093
Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma, Cancer Science, vol.61, issue.10, pp.1115-1124, 2006. ,
DOI : 10.1073/pnas.0501753102
A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model, International Journal of Cancer, vol.32, issue.3, pp.658-663, 2008. ,
DOI : 10.1177/002215549804600204
Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts, Cancer, vol.57, issue.4, pp.864-873, 2006. ,
DOI : 10.1074/jbc.M005911200
Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model, International Journal of Cancer, vol.20, issue.1, pp.216-226, 2011. ,
DOI : 10.1128/MCB.14.5.3230
??-Catenin Small Interfering RNA Successfully Suppressed Progression of Multiple Myeloma in a Mouse Model, Clinical Cancer Research, vol.15, issue.8, pp.2731-2738, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1350
Knockdown of COPA, Identified by Loss-of-Function Screen, Induces Apoptosis and Suppresses Tumor Growth in Mesothelioma Mouse Model, Genomics, vol.95, issue.4, pp.210-216, 2010. ,
DOI : 10.1016/j.ygeno.2010.02.002
delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer, Cancer Science, vol.102, issue.12, pp.1705-1710, 2013. ,
DOI : 10.1111/j.1349-7006.2010.01812.x
ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer, British Journal of Cancer, vol.13, issue.4, pp.700-706, 2011. ,
DOI : 10.1073/pnas.161288698
prolongs the survival of scirrhous gastric cancer model mice, Cancer Science, vol.26, issue.2, pp.214-222, 2013. ,
DOI : 10.1038/sj.onc.1210475
Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells, Biochemical and Biophysical Research Communications, vol.391, issue.1, pp.1075-1079, 2010. ,
DOI : 10.1016/j.bbrc.2009.12.024
Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo, Biochemical and Biophysical Research Communications, vol.399, issue.1, pp.79-83, 2010. ,
DOI : 10.1016/j.bbrc.2010.07.045
Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression, Cell Death & Disease, vol.298, issue.11, p.1514, 2014. ,
DOI : 10.1128/MCB.01266-09
Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway, International Journal of Oncology, vol.45, issue.6, pp.2278-2286, 2014. ,
DOI : 10.3892/ijo.2014.2652
The novel BH3 ??-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein???protein interactions with Bak, Molecular Cancer, vol.12, issue.1, pp.42-2013, 2013. ,
DOI : 10.1371/journal.pone.0048817
Preclinical and clinical development of siRNA-based therapeutics, Advanced Drug Delivery Reviews, vol.87, pp.108-119, 2015. ,
DOI : 10.1016/j.addr.2015.01.007
RNAi Therapies: Drugging the Undruggable, Science Translational Medicine, vol.7, issue.6, pp.240-247, 2014. ,
DOI : 10.1038/nnano.2012.73
Therapeutic targeting in the silent era: advances in non-viral siRNA delivery, Molecular BioSystems, vol.6, pp.1143-1161, 2010. ,
DOI : 10.1039/c001050m
Delivery materials for siRNA therapeutics, Nature Materials, vol.134, issue.11, pp.967-977, 2013. ,
DOI : 10.1021/ja301621z
Single-injection ornithine decarboxylase-directed antisense therapy using atelocollagen to suppress human cancer growth, Cancer, vol.33, issue.5, pp.993-1002, 2007. ,
DOI : 10.4161/cbt.209
A severe combined immunodeficiency mutation in the mouse, Nature, vol.17, issue.5900, pp.527-530, 1983. ,
DOI : 10.1038/301527a0
mRNA turnover rate limits siRNA and microRNA efficacy, Mol Syst Biol, vol.6, p.433, 2010. ,
DOI : 10.1038/msb.2010.113
URL : http://msb.embopress.org/content/6/1/454.full.pdf
Photic and circadian expression of luciferase in mPeriod1-luc transgenic mice in vivo, Proceedings of the National Academy of Sciences, vol.288, issue.5465, pp.489-494, 2002. ,
DOI : 10.1126/science.288.5465.483
Regulation of bcl-2 gene expression in lymphoid cell lines containing normal #18 or t(14;18) chromosomes, Oncogene Res, vol.4, pp.271-282, 1989. ,
Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency, Cancer Cell, vol.21, issue.4, pp.547-562, 2012. ,
DOI : 10.1016/j.ccr.2012.02.028
Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity, Blood, vol.123, issue.18, pp.2806-2815, 2014. ,
DOI : 10.1182/blood-2013-08-519470